Although there are many studies on early-stage cancer, it is not easy to find a health care platform for cancer patients and a program to predict metastatic cancer. In this situation, Ahn Kwang-seong, CEO of PDxen, decided to start his own company to solve the lack of clinical tests. PDxen is researching the field of metastatic cancer based on cell biology.
The leading cause of death in cancer patients is metastatic cancer. Since the survival rate of cancer patients can be maximized when metastatic cancer is detected early, paradigm is changing from an early cancer diagnosis to an early metastatic cancer diagnosis for the treatment of cancer patients.
Many researchers are continuing the
research on predicting the recurrence and metastasis by the CTC (circulating
tumor cell) analysis to find early-stage metastatic cancer not found by CT or
MRI. However, after chemotherapy, the
discovery of cancer cells in the blood has limitations in predicting the
recurrence and metastasis of cancer patients, and when a large number of cancer
cells are found in the blood of cancer patients, the patients may already have
metastatic cancer. Therefore, there is a limitation in predicting the
recurrence and metastasis of cancer patients based on the analysis of the
presence or absence of cancer cells in the blood.
It is reported that metastatic cancer is formed by recurrence and metastasis due to a combination of genetic factors and environmental factors, and that the microscopic long-term environment plays an important role. In addition, recurrent and metastatic cancers are generally observed to be refractory to anticancer drugs, so the anticancer treatment effect of cancer patients is very low, suggesting the cause of death due to metastatic cancer. Therefore, a new anticancer selection platform for metastatic cancer is being required.
After chemotherapy, people rely on CT and MRI every six months to get check ups to diagnose the recurrence and metastasis of cancer. By using PDgen's platform, people can predict the formation of micro-metastatic cancer early by the analysis on cancer cells in blood and clinical information every month, thus maximizing the survival rate of cancer patients by presenting the possibility of early treatment by selecting the target anti-cancer agents that target micro-metastatic cancer.
PDxen (CEO Ahn Kwang-seong) developed the
medical device capable of predicting the presence of micrometastatic cancer
that are not observed in CT or MRI based on the biological properties of cancer
cells in blood and the analysis platform using cancer organoids that can have
similar structure similar to a living environment by analyzing the sensitivity
of cancer cells in blood to anticancer agent based on the genetic analysis of
cancer cells in blood.
PDxen (CEO Ahn Kwang-seong) developed the medical device capable of predicting the presence of micrometastatic cancer that are not observed in CT or MRI based on the biological properties of cancer cells in blood and the analysis platform using cancer organoids that can have similar structure similar to a living environment by analyzing the sensitivity of cancer cells in blood to anticancer agent based on the genetic analysis of cancer cells in blood.
It is primarily sold as research equipment
for the purpose of characterizing the biological properties of cancer cells in
blood. For evaluating the clinical effectiveness by the analysis of the
presence or absence of cancer cells in blood in a bio-like environment and
developing the AI algorithm for the analysis of anti-cancer agent sensitivity
in blood that can form micro-metastatic cancer, PCASI, developed by PDxen, is
currently submitted for medical device registration to use it as a management
platform for personalized cancer patients in clinical field.
The products and services of the major
companies of KHIDI Health Industry Startup Innovation Center in the MIK Hot
Spot (Made in Korea Online Exhibition) will also be displayed in BIO KOREA
2020. Asia's biggest bio convention BIO KOREA 2020 co-organized by KHIDI and
Chungbuk Province and sponsored by MOHW will be open online due to the COVID-29
pandemic on May 18-23. Virtual exhibition halls, conference, and business
forums will be operated, and the companies will be promoting their competitiveness.
Also, with video meetings, businesses between overseas speakers, buyers, and
domestic and foreign participating companies will be made. To date, more than
160 companies have applied for the virtual exhibition booth at BIO KOREA 2020.
Companies wishing to participate can apply through the web page or email by
The global news network AVING News has
begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small
and medium-sized companies enter the market and attract investment 365 days a
year. AVING News has been running online exhibitions since 2005 and had 975
online exhibitions so far. Its YouTube online exhibition has placed itself as
Korea's largest online exhibition hall that opens with 19,000 videos (booths)
with more than 800,000 visits per month which means more than 10 million visits
The MIK Hot Spot online exhibition is scheduled to
be held regularly according to the field, target market, and participating
institutions, and it will be presented as a new type of online business by
transforming the know-hows and values of the participating companies according
to the trend. Companies that want to participate can apply and apply through
the marketing support projects from supporting institutions in the local governments.
Refer to the institutions for more information.